Patents by Inventor Robert D. Mass

Robert D. Mass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20230218755
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: March 14, 2023
    Publication date: July 13, 2023
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20210015918
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 21, 2021
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20200171148
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20190307881
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY
    Publication number: 20190070291
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20180221473
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 9, 2018
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
    Publication number: 20180208647
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: August 15, 2017
    Publication date: July 26, 2018
    Inventors: Napoleone FERRARA, Nina KORSISAARI, Robert D. MASS
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY
    Publication number: 20170360928
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventor: Robert D. Mass
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20160304594
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: March 25, 2016
    Publication date: October 20, 2016
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
    Publication number: 20160108116
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: June 26, 2015
    Publication date: April 21, 2016
    Inventors: Napoleone FERRARA, Nina KORSISAARI, Robert D. MASS
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20150359881
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: January 15, 2015
    Publication date: December 17, 2015
    Inventors: Gwendolyn FYFE, Eric HOLMGREN, Robert D. MASS, William NOVOTNY
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY
    Publication number: 20150150970
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: February 2, 2015
    Publication date: June 4, 2015
    Applicant: GENENTECH, INC.
    Inventor: Robert D. MASS
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY
    Publication number: 20140248609
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 4, 2014
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20140178369
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
    Publication number: 20140178363
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: July 26, 2013
    Publication date: June 26, 2014
    Inventors: Napoleone FERRARA, Nina Korsisaari, Robert D. Mass
  • Gene detection assay for improving the likelihood of an effective response to an EGFR antagonist cancer therapy
    Patent number: 8592152
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 26, 2013
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20130195847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 4, 2012
    Publication date: August 1, 2013
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • Gene detection assay for improving the likelihood of an effective response to a HER2 antibody cancer therapy
    Patent number: 8440402
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: May 14, 2013
    Assignee: Genentech, Inc.
    Inventor: Robert D. Mass
  • TREATMENT WITH ANTI-VEGF ANTIBODIES
    Publication number: 20130028862
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 31, 2013
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
  • VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE THREATMENT OF EARLY STAGE TUMORS
    Publication number: 20120148584
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: February 22, 2012
    Publication date: June 14, 2012
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Nina Korsisaari, Robert D. Mass